Clinical outcomes in patients switched from adalimumab to baricitinib due to non-response and/or study design: phase III data in patients with rheumatoid arthritis.
Yoshiya TanakaBruno FautrelEdward C KeystoneRobert A OrtmannLi XieBaojin ZhuMaher IssaHimanshu PatelCarol L GaichStephanie de BonoTerence P RooneyPeter C TaylorPublished in: Annals of the rheumatic diseases (2019)
NCT01710358, NCT01885078.
Keyphrases
- phase iii
- end stage renal disease
- clinical trial
- open label
- chronic kidney disease
- ejection fraction
- newly diagnosed
- rheumatoid arthritis
- prognostic factors
- peritoneal dialysis
- randomized controlled trial
- electronic health record
- big data
- machine learning
- patient reported outcomes
- phase ii
- double blind
- placebo controlled
- disease activity
- deep learning
- ulcerative colitis
- artificial intelligence
- patient reported